Abstract
Neoplastic transformation of rodent thyroid epithelial cell lines by mutant RAS genes has been widely studied as an experimental model of oncogene-induced loss of tissue-specific differentiation. However, separate evidence strongly implicates RAS mutation as an early event in human thyroid tumour development at a stage prior to loss of differentiation. To resolve this controversy we examined the short- and long-term responses of normal human thyroid epithelial cells to mutant RAS introduced by micro-injection and retroviral transduction respectively. In both cases, expression of RAS at a level sufficient to induce rapid proliferation did not lead to loss of differentiation as shown by expression of cytokeratin 18, E-cadherin, thyroglobulin, TTF-1 and Pax-8 proteins. Indeed, RAS was able to prevent, and to reverse, the loss of thyroglobulin expression which occurs normally in TSH-deficient culture medium. These responses were partially mimicked by activation of RAF, a major RAS effector, indicating involvement of the MAP Kinase signal pathway. The striking contrast between the effect of mutant RAS on differentiation in primary human, compared to immortalized rodent, epithelial cultures is most likely explained by the influence of additional co-operating abnormalities in the latter, and highlights the need for caution in extrapolating from cell line data.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Al-Alawi N, Rose DW, Buckmaster C, Ahn N, Rapp U, Meinkoth J and Feramisco JR. . 1995 Mol. Cell. Biol. 15: 1162–1168.
Avvedimento VE, Musti A, Fusco A, Bonapace MJ and Di Lauro R. . 1988 Proc. Natl. Acad. Sci. USA 85: 1744–1748.
Bond J, Dawson T, Lemoine NR and Wynford-Thomas D. . 1992 Mol. Carcinogen. 5: 129–135.
Bond JA, Wyllie FS, Rowson J, Radulescu A and Wynford-Thomas D. . 1994 Oncogene 9: 281–290.
Brocas H, Christophe D, Pohl V and Vassart G. . 1982 FEBS Lett. 137: 189–192.
Cobellis G, Missero C and Di Lauro R. . 1998 Oncogene 17: 2047–2057.
Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R and Damante G. . 1994 Cancer Res. 54: 4744–4749.
Francis-Lang H, Zannini M, De Felice M, Berlingieri MT, Fusco A and Di Lauro R. . 1992 Mol. Cell Biol. 12: 5793–5800.
Fusco A, Berlingieri MT, DiFiore PP, Portella G, Grieco M and Vecchio G. . 1987 Mol. Cell Biol. 7: 3365–3370.
Gallagher AP, Burnett AK, Dowen DT and Darley RL. . 1998 Cancer Res. 58: 2029–2035.
Gallo A, Benusiglio E, Bonapace IM, Feliciello A, Cassano S, Garbi C, Musti AM, Gottesman ME and Avvedimento EV. . 1992 Genes Dev. 6: 1621–1630.
Gire V, Marshall CJ and Wynford-Thomas D. . 1999 Oncogene 18: 4819–4832.
Gire V and Wynford-Thomas D. . 1998 Mol. Cell. Biol. 18: 1611–1621.
Kupperman E, Wofford D, Wen W and Meinkoth JL. . 1996 Endocrinol. 137: 96–104.
Laker C, Stocking C, Bergholz U, Hess N, DeLamarter JF and Ostertag W. . 1987 Proc. Natl. Acad. Sci. USA 84: 8458–8462.
Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B and Wynford-Thomas D. . 1989 Oncogene 4: 159–164.
Lemoine NR, Staddon S, Bond J, Wyllie FS, Shaw JJ and Wynford-Thomas D. . 1990 Oncogene 5: 1833–1837.
Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G and Dinsart C. . 1987 Nucl. Acids Res. 15: 6735.
Marshall CJ. . 1996 Curr. Biol. 8: 197–204.
Miller MJ, Rioux L, Prendergast GV, Cannon S, White MA and Meinkoth JL. . 1998 Mol. Cell Biol. 18: 3718–3726.
Missero C, Cobellis G, De Felice M and Di Lauro R. . 1998 Mol. Cell Endocrinol. 140: 37–43.
Pohl V, Roger PP, Christophe D, Pattyn G, Vassart G and Dumont JE. . 1990 J. Cell Biol. 111: 663–672.
Roger PP, Christophe D, Dumont JE and Pirson I. . 1997 Eur. J. Endocrinol. 137: 579–598.
Suarez HG, de Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C and Monier R. . 1990 Oncogene 5: 565–570.
Van Renterghem P, Dremier S, Vassart G and Christophe D. . 1995 Mol. Cell Endocrinol. 112: 83–93.
Van Renterghem P, Vassart G and Christophe D. . 1996 Biochim. Biophys. Acta. 1307: 97–103.
Vassart G and Dumont JE. . 1992 Endocrine Rev. 13: 596–611.
Velasco JA, Acebron A, Zannini M, Martin-Perez J, Di Lauro R and Santisteban P. . 1998 Endocrinol. 139: 2796–2802.
Williams DW, Williams ED and Wynford-Thoms D. . 1988 Brit. J. Cancer 57: 535–539.
Zannini M, Acebron A, De Felice M, Arnone MI, Martin-Perez J, Santisteban P and Di Lauro R. . 1996 J. Biol. Chem. 271: 2249–2254.
Acknowledgements
We thank the Cancer Research Campaign and Medical Research Council for grant support, Dr Marian Ludgate for cAMP assay and helpful discussion, Michele Haughton for primary cells, and Dr Van Reterghem (Brussels) and Dr Alan Hall (London) for supply of antibodies and plasmids. The editorial assistance of Theresa King is gratefully acknowledged.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gire, V., Wynford-Thomas, D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 19, 737–744 (2000). https://doi.org/10.1038/sj.onc.1203399
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203399
Keywords
This article is cited by
-
Molecular pathogenesis and mechanisms of thyroid cancer
Nature Reviews Cancer (2013)
-
Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras
The EMBO Journal (2006)
-
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck
Oncogene (2003)
-
RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase
Oncogene (2003)
-
Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells
Oncogene (2001)